Trial Profile
Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacogenomic
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Planned number of patients changed from 50 to 500 as reported by ClinicalTrials.gov.
- 02 May 2012 Planned end date changed from 1 May 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.